Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Cyclacel Pharmaceuticals, Inc. (CYCC)

1.46   0.14 (10.61%) 10-01 10:22
Open: 1.3239 Pre. Close: 1.32
High: 1.51 Low: 1.3
Volume: 234,780 Market Cap: 18(M)
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases. The company's development programs include fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and CYC140, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced leukemias and solid tumors. Its development programs also comprise Sapacitabine, a novel nucleoside analog that is orally available prodrug of CNDAC, which is in Phase 1/2 clinical trials to treat acute myeloid leukemia and myelodysplastic syndrome; and seliciclib, a CDK inhibitor that is in Phase 2 investigator-sponsored trials (IST) for Cushing's disease, as well as in Phase 1/2 IST for the treatment for advanced rheumatoid arthritis. The company has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. Cyclacel Pharmaceuticals, Inc. is headquartered in Berkeley Heights, New Jersey.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 1.51 - 1.52 1.52 - 1.52
Low: 1.29 - 1.29 1.29 - 1.3
Close: 1.45 - 1.46 1.46 - 1.47

Technical analysis

as of: 2022-09-30 4:27:19 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 1.81     One year: 2.06
Support: Support1: 1.2    Support2: 0.99
Resistance: Resistance1: 1.55    Resistance2: 1.76
Pivot: 1.41
Moving Average: MA(5): 1.33     MA(20): 1.47
MA(100): 1.36     MA(250): 2.65
MACD: MACD(12,26): -0.1     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 33.3     %D(3): 23.6
RSI: RSI(14): 50.6
52-week: High: 5.84  Low: 1
Average Vol(K): 3-Month: 973 (K)  10-Days: 158 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CYCC ] has closed below upper band by 40.6%. Bollinger Bands are 0.5% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Wed, 21 Sep 2022
2022-09-21 | NDAQ:CYCC | Press Release | Cyclacel Pharmaceuticals Inc. - Stockhouse

Tue, 13 Sep 2022
Centre signifies Orion’s expansion - News24

Fri, 02 Sep 2022
Securities Litigation Partner James Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Abbott Laboratories To Contact Him Directly To Discuss Their Options - Investing News Network

Fri, 02 Sep 2022
Cyclacel Pharmaceuticals, Inc. (CYCC) Stock Price Today, Quote & News - Seeking Alpha

Fri, 19 Aug 2022
Should You Hold Cyclacel Pharmaceuticals Inc (CYCC) Stock Friday Morning? - InvestorsObserver

Wed, 17 Aug 2022
Cyclacel Pharmaceuticals (NASDAQ:CYCC) Will Have To Spend Its Cash Wisely - Simply Wall St

Financial Analysis

Price to Book Value: Neutral
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 13 (M)
Shares Float 11 (M)
% Held by Insiders 3.6 (%)
% Held by Institutions 33.8 (%)
Shares Short 725 (K)
Shares Short P.Month 856 (K)

Stock Financials

EPS -2.05
EPS Est Next Qtl 0
EPS Est This Year -2.25
EPS Est Next Year -1.58
Book Value (p.s.) 2.66
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -38.1
Return on Equity (ttm) -51.7
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.03
Sales Per Share 0
EBITDA (p.s.) -1.99
Qtrly Earnings Growth 0
Operating Cash Flow -19 (M)
Levered Free Cash Flow -13 (M)

Stock Valuations

PE Ratio -0.72
PEG Ratio 0
Price to Book value 0.54
Price to Sales 0
Price to Cash Flow -0.95

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date 2020-04-14
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.